The important role of neoadjuvant therapy in pancreatic cancer
10.3760/cma.j.cn113884-20200421-00220
- VernacularTitle:重视胰腺癌的新辅助治疗
- Author:
Taiping ZHANG
1
;
Jiangdong QIU
Author Information
1. 中国医学科学院北京协和医院基本外科，北京 100730
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(9):641-644
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is a highly aggressive tumor in the digestive system, and the progress in surgical technique hasn’t improved patients’ prognosis significantly for many years. As the popularization of multidisciplinary team, the role of neoadjuvant therapy has been highlighted in pancreatic cancer. The aim of neoadjuvant therapy is to reduce the tumor size and eliminate micro-metastasis, so as to increase the R 0 resection rate and decrease recurrence and metastasis. Due to the unique tumor microenvironment, pancreatic cancer is not sensitive to chemotherapy and radiotherapy. So neoadjuvant therapy is not effective for all patients, and controversy still exists regarding the patients selection, therapeutic regimen, re-evaluation after neoadjuvant therapy, etc. The application of neoadjuvant therapy is not very mature. At present, we should pay more attention to the role of neoadjuvant therapy in pancreatic cancer. More high-quality clinical researches are urgently needed, and multidisciplinary team should be applied to make personalized treatment strategy in order to improve the prognosis of patients with pancreatic cancer.
